Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaMedica announces encouraging Type 2 diabetes data
In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Reduction in HbA1c is the critical endpoint measurement
In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Reduction in HbA1c is the critical endpoint measurement
Emergent has humanized anti-CD37 mono-specific protein therapeutic, TRU-016, in development for the treatment of B-cell malignancies. The designation provides benefits such as a seven-year period of marketing exclusivity
The syndrome is a condition of the shoulder in which increased capsular collagen thickening and subsequent capsular contraction in the shoulder joint may cause loss of range of
Gattex is a novel, recombinant analog of human glucagon-like peptide 2, which is involved in gastrointestinal regeneration and repair. The NDA is submitted on the basis of 14
The company took the initiative to bring in a new portfolio of packaging solutions following recommendations and input from hospital pharmacy directors from across the US. Cardinal Health
The dietary supplements are sold under brand names including SynBio, SynOPC, BoneCare, SynBio-X, SynOPC-X, VisionCare, CardioCare, SynGevity, SynVita, SynCell, SynPhyto-K, DigestiveCare, JointCare and SynOmega. The US marshals seized
The product comprises blend of taurine, caffeine, guarana extract, cane sugar and lacks artificial flavors and additives, which the company says, gives a yellow appearance and a medicinal
CardioNova will also become an equity investor in AtheroNova. AHRO-001 is indicated to prevent and regress atherosclerotic plaque as well as reduce cholesterol. Maxwell Biotech Venture Fund has
Uceris is a locally acting corticosteroid available in a novel, patented, oral tablet formulation, indicated for induction of remission of active ulcerative colitis. Santarus in collaboration with Cosmo
The project intends to determine the causes of Parkinson’s disease by mapping biological mutations of the Leucine-rich repeat kinase 2 (LRRK2) protein, which is believed to be the